Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors

Clinical Cancer Research

Volumn 15, Issue 9, 2009, Pages 3177-3183

  Plummer, Ruth ^a   Vidal, Laura ^b   Griffin, Melanie ^a   Lesley, Mark ^a   De Bono, Johann ^b   Coulthard, Sally ^a   Sludden, Julieann ^a   Siu, Lillian L ^d   Chen, Eric X ^d   Oza, Amit M ^d   Reid, Gregory K ^c   McLeod, A Robert ^c   Besterman, Jeffrey M ^c   Lee, Chooi ^b   Judson, Ian ^b   Calvert, Hilary ^a   Boddy, Alan V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c METHYLGENE INC   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; MG 98;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GENE EXPRESSION; HEADACHE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TRANSAMINITIS; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENZYME INHIBITORS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; PROGNOSIS; THIONUCLEOTIDES; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 65649152375     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2859     Document Type: Article

References (26)

1. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039-6044
2. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors - state of the art. Ann Oncol 2002;13:1699-1716 (Pubitemid 35439450)
3. Ghoshal K, Bai S. DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) 2007;43:395-422. (Pubitemid 47234771)
4. Brueckner B, Kuck D, Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J 2007;13:17-22.
5. Barrett SV, Lee CP, Appleton KJ, et al. Phase I trial of the DNA hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin both given 4-weekly by intravenous injection in patients with advanced solid tumours. Clin Cancer Res 2005;11:9058S-S.
6. Stewart DJ, Issa JP, Oki Y, et al. Phase I/pharmacodynamic study of decitabine 5 days/week x 2 weeks in advanced cancers. Clin Cancer Res 2005;11:9064S-S.
7. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428 (Pubitemid 34587077)
8. Robert M-F, Morin S, Beaulieu N, et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003;33:61-65
9. Davis AJ, Gelmon KA, Siu LL, et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 2003;21:85-97.
10. Stewart DJ, Donehower RC, Eisenhauer EA, et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 2003;14:766-774
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214 (Pubitemid 11167383)
12. Winquist E, Knox J, Ayoub JP, et al. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs 2006;24:159-167
13. Fournel M, Sapieha P, Beaulieu N, Besterman JM, MacLeod AR. Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cip1) by distinct mechanisms. J Biol Chem 1999;274:24250-24256 (Pubitemid 129528473)
14. Jones PA. DNA methylation and cancer. Cancer Res 1986;46:461-466 (Pubitemid 16145385)
15. Kerbel RS, Frost P, Liteplo R, Carlow DA, Elliott BE. Possible epigenetic mechanisms of tumor progression: induction of high-frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment. J Cell Physiol Suppl 1984;3:87-97. (Pubitemid 14099976)
16. Knox JD, Araujo FD, Bigey P, et al. Inhibition of DNA methyltransferase inhibits DNA replication. J Biol Chem 2000;275:17986-17990
17. Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma 2007;48:1676-1695
18. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-5495
19. Grem JL, Shoemaker DD, Hoth DF, et al. Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials. Invest New Drugs 1987;5:315-328
20. Momparler RL. Pharmacology of 5-aza-2′-deoxycytidine (decitabine). Semin Hematol 2005;42:S9-16. (Pubitemid 40961867)
21. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007;25:4603-4609
22. David AJ, Gelmon KA, Siu LL, et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 2003;21:85-97.
23. Badros A, Goloubeva O, Rapoport AP, et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 2005;23:4089-4099
24. Dritschilo A, Huang CH, Rudin CM, et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusionin combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 2006;12:1251-1259
25. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005;97:1498-1506 (Pubitemid 41631949)
26. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 2005;65:7086-7090 (Pubitemid 41161236)